{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:03Z","timestamp":1791327423841,"version":"4.3.1"},"reference-count":257,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00033","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T11:26:42Z","timestamp":1549625202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":209,"title":["The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management"],"prefix":"10.3389","volume":"10","author":[{"given":"Smita Y.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J Clin Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency - causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10875-007-9103-1","article-title":"Population prevalence of diagnosed primary immunodeficiency diseases in the United States","volume":"27","author":"Boyle","year":"2007","journal-title":"J Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1016\/j.jaci.2009.08.040","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig."},{"key":"B9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.7326\/0003-4819-114-11-924","article-title":"PLasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis","volume":"114","author":"Pohl","year":"1991","journal-title":"Ann Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B12","year":"2017","journal-title":"Historical Audit Analysis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol."},{"key":"B14","unstructured":"Cancer Stat Facts: Myeloma."},{"key":"B15","unstructured":"Cancer Stat Facts: LeumQ14kemia - Chronic Lymphocytic Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1056\/NEJMoa1215637","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/1348-0421.12060","article-title":"Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections","volume":"57","author":"Gunther","year":"2013","journal-title":"Microbiol Immunol."},{"key":"B20","author":"Adivo","year":"2016","journal-title":"Market Research: immunoglobulin Usage in SID"},{"key":"B21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cei.12493","article-title":"Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies","volume":"178","author":"Sepp\u00e4nen","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2014.00257","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"5","author":"Tete","year":"2014","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.V57.3.418.bloodjournal573418","article-title":"Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation","volume":"57","author":"Kay","year":"1981","journal-title":"Blood"},{"key":"B25","first-page":"283","article-title":"An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL","volume":"30","author":"Dighiero","year":"1988","journal-title":"Nouv Rev Fr Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull."},{"key":"B27","unstructured":"Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction316874 SampaloA NavasG MedinaF SegundoC CamaraC BrievaJA 11049999Blood962000"},{"key":"B28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"INfections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-07-4435","article-title":"Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma","volume":"14","author":"Ansell","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0961203309102803","article-title":"An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus","volume":"18","author":"Pena-Rossi","year":"2009","journal-title":"Lupus"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","article-title":"Atacicept in relapsed\/refractory multiple myeloma or active Waldenstr\u00f6m's macroglobulinemia: a phase I study","volume":"101","author":"Rossi","year":"2009","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two\u2013week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1177\/0961203317695465","article-title":"Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine","volume":"26","author":"Nagel","year":"2017","journal-title":"Lupus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.27621","article-title":"Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al","volume":"62","author":"Wallace","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1002\/art.34564","article-title":"Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus","volume":"64","author":"Merrill","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3899\/jrheum.120886","article-title":"Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study","volume":"40","author":"Stohl","year":"2013","journal-title":"J Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjogren's syndrome: results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B51","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological malignancies","volume":"57","author":"Gafter-Gvili","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/10428194.2015.1046862","article-title":"Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study","volume":"57","author":"Gafter-Gvili","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell\u2013engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5045\/kjh.2010.45.3.188","article-title":"The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma","volume":"45","author":"Yi","year":"2010","journal-title":"Korean J Hematol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/0016-5085(86)90183-6","article-title":"Randomized trial of chlorambucil for primary biliary cirrhosis","volume":"91","author":"Hoofnagle","year":"1986","journal-title":"Gastroenterology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF01714955","article-title":"Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass","volume":"63","author":"Montserrat","year":"1991","journal-title":"Ann Hematol."},{"key":"B67","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.leu.2401368","article-title":"2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger","volume":"13","author":"Robak","year":"1999","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O","article-title":"A pilot study of 2-chloro-2\u2032-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis","volume":"41","author":"Davis","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2018.152","article-title":"Clozapine is associated with secondary antibody deficiency","author":"Ponsford","year":"","journal-title":"Br J Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0893-133X(98)00006-2","article-title":"Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients","volume":"19","author":"Hinze-Selch","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/2045125315591925","article-title":"Effect of clozapine on immunoglobulin M plasma levels","volume":"6","author":"Lozano","year":"2016","journal-title":"Ther Adv Psychopharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s10875-016-0264-7","article-title":"Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency","volume":"36","author":"Wirsum","year":"2016","journal-title":"J Clin Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1378\/chest.110.2.367","article-title":"Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids","volume":"110","author":"Kubiet","year":"1996","journal-title":"CHEST"},{"key":"B75","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"S702","DOI":"10.1093\/ofid\/ofx163.1884","article-title":"Infection risk associated with daratumumab","volume":"4","author":"Johnsrud","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of Epratuzumab, an Anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sj\u00f6gren's Syndrome: post hoc analyses from the EMBODY trials","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma","volume":"10","author":"Leonard","year":"2004","journal-title":"Phase I\/II Clin Trial Results"},{"key":"B80","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"D\u00f6rner","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/14397595.2015.1079292","article-title":"Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: results from a phase 1\/2 randomized study","volume":"26","author":"Tsuru","year":"2016","journal-title":"Modern Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-kappaB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"B92","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1352458517740641","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","author":"Agius","year":"2017","journal-title":"Mult Scler J."},{"key":"B97","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/13.1.160","article-title":"Suppression of the humoral immune response by mycophenolate mofetil","volume":"13","author":"Smith","year":"1998","journal-title":"Nephrol Dialys Transplant."},{"key":"B99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0041-1345(01)02683-5","article-title":"Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation","volume":"34","author":"Munoz","year":"2002","journal-title":"Transplant Proc."},{"key":"B100","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.200510-1609OC","article-title":"Immunoglobulin G levels before and after lung transplantation","volume":"173","author":"Yip","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-015-0603-8","article-title":"Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus","volume":"17","author":"Fassbinder","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00296-015-3265-6","article-title":"Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus","volume":"35","author":"Subedi","year":"2015","journal-title":"Rheumatol Int."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3899\/jrheum.110994","article-title":"Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a Placebo-Controlled Double-Blind Parallel-group Study","volume":"39","author":"Harigai","year":"2012","journal-title":"J Rheumatol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/art.33353","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight\u2013week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Tak","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B109","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"Lim","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B112","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/j.1349-7006.2011.02001.x","article-title":"Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study","volume":"102","author":"Tobinai","year":"2011","journal-title":"Cancer Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2014incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM Int J Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/acr.22921","article-title":"Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years","volume":"69","author":"Aguiar","year":"2016","journal-title":"Arthritis Care Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/ckj\/sfx014","article-title":"Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Shah","year":"2017","journal-title":"Clin Kidney J."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1172\/JCI107031","article-title":"The effect of azathioprine on gammaglobulin synthesis in man","volume":"51","author":"Levy","year":"1972","journal-title":"J Clin Investig."},{"key":"B120","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight\u2013week randomized, double-blind trial","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum."},{"key":"B121","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1399-3062.2003.00035.x","article-title":"Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine","volume":"5","author":"Keven","year":"2003","journal-title":"Transplant Infect Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ibd.21688","article-title":"Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines","volume":"18","author":"Dotan","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant."},{"key":"B125","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.healun.2016.10.004","article-title":"Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study","volume":"36","author":"Sarmiento","year":"2017","journal-title":"J Heart Lung Transplant."},{"key":"B126","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1016\/j.transproceed.2005.09.153","article-title":"Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation","volume":"37","author":"Sarmiento","year":"2005","journal-title":"Transplant Proc."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"The effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in ANCA vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/ACI.0000000000000485","article-title":"Secondary antibody deficiency in neurology","volume":"18","author":"Tallantyre","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest."},{"key":"B132","first-page":"483","article-title":"Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar","year":"2014","journal-title":"P T."},{"key":"B133","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.4049\/jimmunol.1401550","article-title":"A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy","volume":"193","author":"Golay","year":"2014","journal-title":"J Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/10428194.2015.1085531","article-title":"Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*","volume":"57","author":"Kalaycio","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B135","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/13543784.2018.1459560","article-title":"Ublituximab for the treatment of CD20 positive B-cell malignancies","volume":"27","author":"Babiker","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14712598.2017.1377178","article-title":"Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders","volume":"17","author":"Said","year":"2017","journal-title":"Expert Opin Biol Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology"},{"key":"B138","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett."},{"key":"B139","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/1744666X.2018.1450141","article-title":"Epratuzumab for the treatment of systemic lupus erythematosus","volume":"14","author":"Geh","year":"2018","journal-title":"Expert Rev Clin Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3109\/10428194.2015.1028052","article-title":"Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas","volume":"56","author":"Martin","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B141","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"key":"B142","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities \u2013 analysis of 5 prospective clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2147\/TCRM.S148586","article-title":"Current treatment options for psoriatic arthritis: spotlight on abatacept","volume":"14","author":"Ursini","year":"2018","journal-title":"Ther Clin Risk Manag."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"key":"B145","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12860","article-title":"Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus","volume":"81","author":"Witcher","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2147\/DDDT.S71276","article-title":"Profile of atacicept and its potential in the treatment of systemic lupus erythematosus","volume":"9","author":"Cogollo","year":"2015","journal-title":"Drug Design Dev Ther."},{"key":"B147","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B150","doi-asserted-by":"publisher","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","article-title":"Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program","volume":"9","author":"Emery","year":"2014","journal-title":"PLoS ONE"},{"key":"B151","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B152","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/art.39809","article-title":"Post hoc Analysis of the Phase II\/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL","volume":"69","author":"Gordon","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus","volume":"70","author":"Merrill","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial","volume":"67","author":"van Vollenhoven","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs"},{"key":"B159","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B160","unstructured":"2016"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.rcl.2015.09.009","article-title":"Complications of immunosuppressive agents therapy in transplant patients","volume":"81","author":"Reske","year":"2015","journal-title":"Minerva Anestesiol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1034\/j.1399-3062.2001.00008.x","article-title":"Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes","volume":"3","author":"Yamani","year":"2001","journal-title":"Transpl Infect Dis."},{"key":"B163","unstructured":"Heart\/Lung Registries2017"},{"key":"B164","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.intimp.2006.09.011","article-title":"Impaired anti-pneumococcal polysaccharide antibody production and invasive pneumococcal infection following heart transplantation","volume":"6","author":"Sarmiento","year":"2006","journal-title":"Int Immunopharmacol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J Neurol Sci."},{"key":"B168","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1586\/1744666X.2014.902314","article-title":"Secondary antibody deficiency","volume":"10","author":"Duraisingham","year":"2014","journal-title":"Expert Rev Clin Immunol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"63","DOI":"10.9740\/mhc.2018.03.063","article-title":"Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy","volume":"8","author":"Curry","year":"2018","journal-title":"Mental Health Clin."},{"key":"B170","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B171","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/MOT.0b013e32833b9cb7","article-title":"Complement in organ transplantation","volume":"15","author":"Asgari","year":"2010","journal-title":"Curr Opin Organ Transplant."},{"key":"B172","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1038\/cti.2014.3","article-title":"Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation","volume":"3","author":"Fernandez-Ruiz","year":"2014","journal-title":"Clin Transl Immunol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/ajt.12055","article-title":"Hypocomplementemia in kidney transplant recipients: impact on the risk of infectious complications","volume":"13","author":"Fernandez-Ruiz","year":"2013","journal-title":"Am J Transplant."},{"key":"B174","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1399-3062.2008.00329.x","article-title":"Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection","volume":"10","author":"Carbone","year":"2008","journal-title":"Transpl Infect Dis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1399-3062.2012.00757.x","article-title":"Decreased levels of serum complement C3 and natural killer cells add to the predictive value of total immunoglobulin G for severe infection in heart transplant recipients","volume":"14","author":"Sarmiento","year":"2012","journal-title":"Transpl Infect Dis."},{"key":"B176","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1034\/j.1399-3062.2000.020306.x","article-title":"Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?","volume":"2","author":"Corales","year":"2000","journal-title":"Transpl Infect Dis."},{"key":"B177","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.healun.2007.07.010","article-title":"Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?","volume":"26","author":"Munoz","year":"2007","journal-title":"J Heart Lung Transplant."},{"key":"B178","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.intimp.2008.09.013","article-title":"Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation","volume":"9","author":"Sarmiento","year":"2009","journal-title":"Int Immunopharmacol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(97)08486-9","article-title":"Effect of immunosuppression after cardiac transplantation in early childhood on antibody response to polysaccharide antigen","volume":"351","author":"Gennery","year":"1998","journal-title":"Lancet"},{"key":"B180","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1023\/A:1006741015452","article-title":"Lymphocyte subset populations in children with polysaccharide antibody deficiency following cardiac transplantation","volume":"21","author":"Gennery","year":"2001","journal-title":"J Clin Immunol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1086\/515671","article-title":"Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients","volume":"178","author":"Lazzarotto","year":"1998","journal-title":"J Infect Dis."},{"key":"B182","first-page":"405","article-title":"Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies","volume":"13","author":"Iberer","year":"1994","journal-title":"J Heart Lung Transplant."},{"key":"B183","doi-asserted-by":"publisher","first-page":"E277","DOI":"10.1111\/j.1399-0012.2012.01653.x","article-title":"Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections","volume":"26","author":"Carbone","year":"2012","journal-title":"Clin Transplant."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1084\/jem.20042384","article-title":"Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells","volume":"201","author":"Bunde","year":"2005","journal-title":"J Exp Med."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.105.607549","article-title":"T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease","volume":"114","author":"Tu","year":"2006","journal-title":"Circulation"},{"key":"B186","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/tid.12284","article-title":"Evaluation of an immunological score to assess the risk of severe infection in heart recipients","volume":"16","author":"Sarmiento","year":"2014","journal-title":"Transpl Infect Dis."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.clinthera.2017.07.005","article-title":"A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients","volume":"39","author":"Chong","year":"2017","journal-title":"Clin Ther."},{"key":"B188","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5414\/CN107779","article-title":"Large decrease of anti-tetanus anatoxin and anti-pneumococcal antibodies at one year after renal transplantation","volume":"79","author":"Broeders","year":"2013","journal-title":"Clin Nephrol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/bmt.2013.76","article-title":"Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT","volume":"48","author":"Frangoul","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B190","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood.V58.2.360.bloodjournal582360","article-title":"Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment","volume":"58","author":"Witherspoon","year":"1981","journal-title":"Blood"},{"key":"B191","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2010-07-295766","article-title":"Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia","volume":"117","author":"Kuzmina","year":"2011","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.bbmt.2014.01.002","article-title":"Immune cell subset counts associated with graft-versus-host disease","volume":"20","author":"Podgorny","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"B194","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"key":"B197","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1128\/CMR.16.3.357-364.2003","article-title":"Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols","volume":"16","author":"Duchini","year":"2003","journal-title":"Clin Microbiol Rev."},{"key":"B198","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1542\/peds.99.1.35","article-title":"Varicella and zoster in children after kidney transplantation: long-term results of vaccination","volume":"99","author":"Broyer","year":"1997","journal-title":"Pediatrics"},{"key":"B199","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1111\/j.1600-6143.2009.02917.x","article-title":"Guidelines for vaccination of solid organ transplant candidates and recipients","volume":"9","author":"Danzinger-Isakov","year":"2009","journal-title":"Am J Transplant."},{"key":"B200","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1097\/TP.0000000000001685","article-title":"Long-term follow-up of humoral immune status in adult lung transplant recipients","volume":"101","author":"van Kessel","year":"2017","journal-title":"Transplantation"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3346\/jkms.2016.31.12.1937","article-title":"Antibodies against Hepatitis A and Hepatitis B virus in intravenous immunoglobulin products","volume":"31","author":"Lee","year":"2016","journal-title":"J Korean Med Sci."},{"key":"B202","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2172-15-26","article-title":"Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study","volume":"15","author":"Nobre","year":"2014","journal-title":"BMC Immunol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines \u2013 what's the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"key":"B204","unstructured":"General recommendations on immunization \u2014 recommendations of the Advisory Committee on Immunization Practices (ACIP)164MMWR Recomm Rep.602011"},{"key":"B205","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","journal-title":"N Engl J Med."},{"key":"B207","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","article-title":"Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin","volume":"53","author":"Jurlander","year":"1994","journal-title":"Eur J Haematol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","article-title":"Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes","volume":"88","author":"Chapel","year":"1994","journal-title":"Br J Haematol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1159\/000227231","article-title":"Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma","volume":"50","author":"Sklenar","year":"1993","journal-title":"Oncology"},{"key":"B210","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood"},{"key":"B211","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol."},{"key":"B212","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"B213","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/0140-6736(90)92016-B","article-title":"Consensus on IVIG","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"B214","unstructured":"Guideline on Core SmPC for Human Normal Immunoglobulin for Intravenous Administration (IVIg): EMA2018"},{"key":"B215","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJM199201093260216","article-title":"Prophylactic immune globulin in chronic lymphocytic leukemia","volume":"326","author":"Besa","year":"1992","journal-title":"N Engl J Med."},{"key":"B216","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","article-title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","volume":"127","author":"Ammann","year":"2016","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev."},{"key":"B218","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"B220","unstructured":"JollesS Subcutaneous and Intramuscular Immune Globulin Therapy2018"},{"key":"B221","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol."},{"key":"B222","first-page":"160","article-title":"Immunoglobulin replacement therapy by self-infusion at home","volume":"73","author":"Chapel","year":"1988","journal-title":"Clin Exp Immunol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/tid.12610","article-title":"Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial","volume":"18","author":"Sarmiento","year":"2016","journal-title":"Transpl Infect Dis."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.healun.2004.11.016","article-title":"The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study","volume":"24","author":"Yamani","year":"2005","journal-title":"J Heart Lung Transplant."},{"key":"B225","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/j.transproceed.2007.06.050","article-title":"The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections","volume":"39","author":"Carbone","year":"2007","journal-title":"Transplant Proc."},{"key":"B226","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.intimp.2004.09.006","article-title":"Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease","volume":"5","author":"Sarmiento","year":"2005","journal-title":"Int Immunopharmacol."},{"key":"B227","unstructured":"Guideline on the Clinical Investigation of Human Normal Immunoglobulin for Subcutaneous and\/or Intramuscular Administration (SCIg\/IMIg): EMA2015"},{"key":"B228","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol."},{"key":"B229","unstructured":"Clinical Guidelines for Immunoglobulin Use2011"},{"key":"B230","unstructured":"Acquired Hypogammaglobulinaemia Secondary to Haematological Malignancies, or Post-Haemopoietic Stem Cell Transplantation (HSCT): BloodStar2018"},{"key":"B231","unstructured":"Secondary Hypogammaglobulinaemia Unrelated to Haematological Malignancy or Haemopoeitic Stem Cell Transplant (HSCT): BloodStar2018"},{"key":"B232","unstructured":"Criteria for the Clinical Use of Immune Globulin2018"},{"key":"B233","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12594","article-title":"Cytomegalovirus infection in solid organ transplant recipients","volume":"20","author":"Lumbreras","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"B234","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B235","unstructured":"Guideline on the Clinical Investigation of Human Normal Immunoglobulin for Intravenous Administration (IVIg): EMA2018"},{"key":"B236","unstructured":"The efficacy and cost effectiveness of Subcutaneous Immunoglobulin (SCIG) replacement in patients with immune deficiency secondary to chronic lymphocytic leukemia4778 StreuE BanerjiV DhaliwalDHS Blood1282016"},{"key":"B237","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1586\/eci.13.30","article-title":"A review on guidelines for management and treatment of common variable immunodeficiency","volume":"9","author":"Abolhassani","year":"2013","journal-title":"Expert Rev Clin Immunol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B239","unstructured":"Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases2009"},{"key":"B240","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/cei.13105","article-title":"Measurement of Typhim Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency","volume":"192","author":"Evans","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2018.05.013","article-title":"Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity","volume":"459","author":"Parker","year":"2018","journal-title":"J Immunol Methods"},{"key":"B242","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/cei.12369","article-title":"Calculated globulin (CG) as a screening test for antibody deficiency","volume":"177","author":"Jolles","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/ACI.0000000000000222","article-title":"Current screening approaches for antibody deficiency","volume":"15","author":"Holding","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B244","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/01.WNL.0000113754.29225.5D","article-title":"Lamotrigine-induced common variable immune deficiency","volume":"62","author":"Smith","year":"2004","journal-title":"Neurology"},{"key":"B245","first-page":"353","article-title":"Rapidly fatal dissemination of merkel cell carcinoma in a patient treated with alemtuzumab for chronic lymphocytic leukemia","volume":"80","author":"Yu","year":"2016","journal-title":"Conn Med."},{"key":"B246","unstructured":"The risk factors for IgG hypogammaglobulinemia after allogeneic hematopoietic stem cell transplantation and its impact on transplant outcomes3928 UhmJ HamadN GuptaV KuruvillaJ MessnerHA SeftelM Blood1242014"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1159\/000449163","article-title":"Secondary combined immunodeficiency in pediatric patients after the fontan operation: three case reports","author":"Hlavackova","year":"","journal-title":"Int Arch Allergy Immunol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"B249","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/B978-0-12-370725-3.50015-4","article-title":"Use of immunoglobulin therapy in secondary antibody deficiencies","volume-title":"Immunotherapy With Intravenous Immunoglobulins.","author":"Stiehm","year":"1991"},{"key":"B250","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/adc.82.3.234","article-title":"Proteus syndrome and immunodeficiency","volume":"82","author":"Hodge","year":"2000","journal-title":"Arch Dis Child."},{"key":"B251","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/heart.89.10.1130","article-title":"Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation","volume":"89","author":"Chakrabarti","year":"2003","journal-title":"Heart"},{"key":"B253","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/INF.0b013e3182815064","article-title":"Invasive pneumococcal infection secondary to hypogammaglobulinemia due to Menetrier disease","volume":"32","author":"Dominguez-Pinilla","year":"2013","journal-title":"Pediatr Infect Dis J."},{"key":"B254","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.clineuro.2011.02.003","article-title":"IgG deficiency and expansion of CTG repeats in myotonic dystrophy","volume":"113","author":"Kaminsky","year":"2011","journal-title":"Clin Neurol Neurosurg."},{"key":"B255","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3324\/haematol.12642","article-title":"Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor","volume":"93","author":"Santachiara","year":"2008","journal-title":"Haematologica"},{"key":"B256","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00043426-200102000-00011","article-title":"Hypogammaglobulinemia and reduced numbers of B-cells in children with myelodysplastic syndrome","volume":"23","author":"Srivannaboon","year":"2001","journal-title":"J Pediatr Hematol Oncol."},{"key":"B257","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00431-010-1235-2","article-title":"Clinical practice: protein-losing enteropathy in children","volume":"169","author":"Braamskamp","year":"2010","journal-title":"Eur J Pediatrics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T11:03:20Z","timestamp":1573902200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":257,"alternative-id":["10.3389\/fimmu.2019.00033"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00033","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"article-number":"33"}}